Equillium, Inc.

NasdaqCM:EQ Stock Report

Market Cap: US$137.8m

Equillium Future Growth

Future criteria checks 0/6

Equillium's earnings are forecast to decline at 27.6% per annum. EPS is expected to decline by 10.7% per annum.

Key information

-27.6%

Earnings growth rate

-10.74%

EPS growth rate

Biotechs earnings growth25.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Good

Last updated15 May 2026

Recent future growth updates

Recent updates

Analysis Article • Nov 10

Investors Don't See Light At End Of Equillium, Inc.'s (NASDAQ:EQ) Tunnel

Equillium, Inc.'s ( NASDAQ:EQ ) price-to-sales (or "P/S") ratio of 4x might make it look like a strong buy right now...
Analysis Article • Jul 18

Equillium, Inc.'s (NASDAQ:EQ) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Those holding Equillium, Inc. ( NASDAQ:EQ ) shares would be relieved that the share price has rebounded 28% in the last...
Analysis Article • Mar 31

Revenues Working Against Equillium, Inc.'s (NASDAQ:EQ) Share Price Following 47% Dive

Equillium, Inc. ( NASDAQ:EQ ) shareholders that were waiting for something to happen have been dealt a blow with a 47...
Analysis Article • Feb 12

Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Equillium, Inc. ( NASDAQ:EQ ) shares have had a really impressive month, gaining 27% after a shaky period beforehand...
Analysis Article • Nov 16

Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge

Equillium, Inc. ( NASDAQ:EQ ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • Sep 26

Lacklustre Performance Is Driving Equillium, Inc.'s (NASDAQ:EQ) 28% Price Drop

The Equillium, Inc. ( NASDAQ:EQ ) share price has softened a substantial 28% over the previous 30 days, handing back...
Analysis Article • Jun 16

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Unfortunately for some shareholders, the Equillium, Inc. ( NASDAQ:EQ ) share price has dived 54% in the last thirty...
Analysis Article • May 01

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 27

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

With a price-to-sales (or "P/S") ratio of 2x Equillium, Inc. ( NASDAQ:EQ ) may be sending very bullish signals at the...
Analysis Article • Aug 14

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Equillium, Inc. ( NASDAQ:EQ ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Aug 12

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

A week ago, Equillium, Inc. ( NASDAQ:EQ ) came out with a strong set of quarterly numbers that could potentially lead...
Analysis Article • May 03

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Equillium, Inc. ( NASDAQ:EQ ) shareholders will have a reason to smile today, with the analysts making substantial...
Analysis Article • Mar 26

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Aug 15

Equillium GAAP EPS of -$0.41 in-line

Equillium press release (NASDAQ:EQ): Q2 GAAP EPS of -$0.41 in-line. Cash, cash equivalents and short-term investments totaled $57.6 million as of June 30, 2022, compared to $68.8 million as of March 31, 2022.
Seeking Alpha • Oct 08

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium is a clinical-stage biotech company treating severe autoimmune and inflammatory disorders. CEO Bruce Steel discusses primary drug itolizumab pivotal study. Alternative to short-term, high dose steroid therapies.
Analysis Article • Mar 09

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Every investor in Equillium, Inc. ( NASDAQ:EQ ) should be aware of the most powerful shareholder groups. Large...
Analysis Article • Nov 24

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

A look at the shareholders of Equillium, Inc. (NASDAQ:EQ) can tell us which group is most powerful. Institutions often...

Earnings and Revenue Growth Forecasts

NasdaqCM:EQ - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-50-50-456
12/31/2027N/A-36-39-357
12/31/2026N/A-27-24-237
3/31/2026N/A-19-19-19N/A
12/31/2025N/A-22-23-23N/A
9/30/20254-24-23-23N/A
6/30/202517-20-22-22N/A
3/31/202530-14-18-18N/A
12/31/202441-8-19-19N/A
9/30/202446-5-22-21N/A
6/30/202443-8-16-16N/A
3/31/202438-12-23-23N/A
12/31/202336-13-22-22N/A
9/30/202343-81212N/A
6/30/202334-1800N/A
3/31/202325-29-5-5N/A
12/31/202216-62-9-9N/A
9/30/2022N/A-76-47-47N/A
6/30/2022N/A-72-41-41N/A
3/31/2022N/A-67-37-36N/A
12/31/2021N/A-39-32-32N/A
9/30/2021N/A-37-30-30N/A
6/30/2021N/A-34-28-28N/A
3/31/2021N/A-31-26-26N/A
12/31/2020N/A-30-25-25N/A
9/30/2020N/A-28-26-25N/A
6/30/2020N/A-28-25-25N/A
3/31/2020N/A-27-25-25N/A
12/31/2019N/A-26N/A-23N/A
9/30/2019N/A-23N/A-18N/A
6/30/2019N/A-22N/A-15N/A
3/31/2019N/A-18N/A-11N/A
12/31/2018N/A-13N/A-8N/A
9/30/2018N/A-10N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EQ is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: EQ is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: EQ is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if EQ's revenue is forecast to grow faster than the US market.

High Growth Revenue: EQ is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EQ's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 00:52
End of Day Share Price 2026/05/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Equillium, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William WoodB. Riley Securities, Inc.
Steven SeedhouseCantor Fitzgerald & Co.
Roger SongJefferies LLC